Slide 1: Evotec First Quarter 2026 Results
Evotec First Quarter 2026 Results Building Transformation Momentum May 6, 2026
Slide 2: Today's Speakers
Today’s Speakers Christian Wojczewski Business Update CEO Claire Hinshelwood Financial Update CFO Cord Dohrmann Q&A Availability CSO PAGE 2
Slide 3: Disclaimer
Disclaimer Cautionary Note Regarding Forward-Looking Statements This presentation (including any information which has been or may be supplied This presentation contains forward-looking statements concerning our business, in writing or orally in connection here with or in connection with any further
Slide 4: Highlights: Focused Execution and Strategic Transition
Highlights: Focused Execution and Strategic Transition A quarter of operational focus and leadership transition Management Update Segment News Flow Q1 2026 Group Reporting Leadership Continuity Partnership Progress Group €156.6 m revenues: 166.9 m at CER Orderly CFO transition and Speed, reliability
Slide 5: Chief Financial Officer: Transition of Financial Leadership
Chief Financial Officer: Transition of Financial Leadership Ensuring continuity in advancing financial discipline Claire Hinshelwood • >30 years of financial leadership experience, with a Mandate & Priorities career focused on finance transformation, performance management and governance • Ensure co
Slide 6: New Chief Operating Officer: Strengthening Operational Excellence
New Chief Operating Officer: Strengthening Operational Excellence Driving execution and advancing the Horizon transformation Ingrid Müller • >20 years of international leadership experience Mandate & Priorities across operations, strategy, supply, procurement and R&D integration in the life sciences
Slide 7: AI-Enabled D&PD Platforms Driving Speed and Quality
AI-Enabled D&PD Platforms Driving Speed and Quality Advancing partnered programs through differentiated and advanced platforms Discovery & Preclinical Development Almirall Collaboration: Medical Dermatology Integrated AI-enabled platforms, producing high-value candidates • First preclinical developm
Slide 8: Condensed Income Statement First Quarter 2026
Condensed Income Statement First Quarter 2026 Reported performance impacted by strong prior-year comparison and currency effects Three month ended Mar 31, in € m1 2026 2025 Change External Revenues 156.6 200.0 -43.4 D&PD 119.9 140.6 -20.7 JEB 36.8 59.4 -22.6 Gross margin -1.6 33.28 -34.85 D&PD 7.2 2
Slide 9: Q1 2026: Bridging Reported Results and Underlying Performance
Q1 2026: Bridging Reported Results and Underlying Performance Extraordinary prior-year effects and FX headwinds drive reported decline Q1 2025 Comparison €200,0 Adjusted for One-offs and FX Impacts €23,1 -6% €166,6 Group €10,2 €156,6 • Revenues decreased 6%, adjusted for Sandoz license sale and FX-i
Slide 10: Quarterly Liquidity Development
Quarterly Liquidity Development Solid balance sheet with net cash position at the end of the first quarter 2026 Net debt (net cash) 43 107 114 246 (40) (10) in € million Favorable changes in working 1 capital versus Q1 2025 supporting improved operating cash flow Disciplined capital expenditures 476
Slide 11: Horizon: Transforming Evotec for Sustainable Growth
Horizon: Transforming Evotec for Sustainable Growth Multi-stage transition well on track and moving into execution Reduce global footprint from • Majority of works council consultations currently 14 sites to 10 expected to conclude mid-2026 Reduce workforce by approx. • Initial personnel adjustments
Slide 12: Continuing Momentum Across Leading Commercial Indicators
Continuing Momentum Across Leading Commercial Indicators Improving funnel activity and early signs of stabilization Reduction of negative Increase of number Reduction of proposal Positive net sales change orders of proposals turn-around time order progression Further improved Highest level in Improv
Slide 13: Key Messages
Key Messages Focused execution and foundations for renewed momentum • Full-year guidance confirmed: Q1 2026 performance in line with expectations amid continued softness in early-stage drug discovery market and foreign exchange headwinds • Early signs of commercial stabilization: Improving indicator
Slide 14: Thank you
Thank you Dr. Sarah Fakih EVP Head of Global Communications & Investor Relations +49 (0) 151 7068 8784 (m) sarah.fakih@evotec.com